An investigational GLP-1 and glucagon receptor dual agonist studied mainly in China for obesity and type 2 diabetes, where the added glucagon activity may raise energy expenditure and lower liver fat.
Reviewed for accuracy · Last reviewed July 8, 2026Mazdutide (also called IBI362 or LY3305677) activates two metabolic receptors at once: GLP-1, which curbs appetite and slows gastric emptying, and glucagon, which is proposed to increase energy expenditure and reduce hepatic fat. Its development has centered on Chinese trial populations, where Phase 2 and Phase 3 studies reported dose-dependent weight loss alongside improvements in cardiometabolic markers.
It is given as a once-weekly subcutaneous injection, usually started low and stepped up over several weeks. Mazdutide gained China NMPA approval for weight management and glycemic control in 2025 but is not FDA- or EMA-approved, so any independent use is investigational and unlabeled.
Trials used once-weekly subcutaneous doses from 3 mg through 6 mg (Phase 2 and GLORY-1) up to a 9 mg maintenance arm (GLORY-2). Mazdutide is investigational outside China, so there is no approved prescribing dose for independent use.
Read the full Mazdutide dosage guide →Across trials the most common adverse events were gastrointestinal (nausea, diarrhea, vomiting) plus reduced appetite, generally mild to moderate and dose-related.
Read the full Mazdutide side effects guide →Keep unmixed vials refrigerated and away from light. Once reconstituted, most research reports store it refrigerated for roughly 3–4 weeks. See the full storage & safety guide for handling and disposal basics.
This page is an independent educational reference and is not medical advice, and does not indicate any approval status for any use. Talk to a doctor before starting any compound.